FDA — authorised 1 December 2020
- Marketing authorisation holder: UNIV CA LOS ANGELES
- Status: approved
🇺🇸 Locametz in United States
FDA authorised Locametz on 1 December 2020
Marketing authorisations
FDA — authorised 17 December 2021
- Application: NDA214032
- Marketing authorisation holder: TELIX
- Local brand name: ILLUCCIX
- Indication: POWDER — INTRAVENOUS
- Status: approved
FDA — authorised 23 March 2022
- Application: NDA215841
- Marketing authorisation holder: NOVARTIS
- Local brand name: LOCAMETZ
- Indication: POWDER — INTRAVENOUS
- Status: approved
Locametz in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Locametz approved in United States?
Yes. FDA authorised it on 1 December 2020; FDA authorised it on 17 December 2021; FDA authorised it on 23 March 2022.
Who is the marketing authorisation holder for Locametz in United States?
UNIV CA LOS ANGELES holds the US marketing authorisation.